NFA
CRVS icon

Nationwide Fund Advisors’s Corvus Pharmaceuticals CRVS Stock Holding History

Nationwide Fund Advisors’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-74,513
Closed -$1.19M – 483
2017
Q3 		$1.19M Sell
74,513
-2,300
-3% -$31.8K ﹤0.01% 1688
2017
Q2 		$929K Buy
76,813
+56,856
+285% +$607K ﹤0.01% 1819
2017
Q1 		$415K Sell
19,957
-3,600
-15% -$56.4K ﹤0.01% 2249
2016
Q4 		$337K Sell
23,557
-1,000
-4% -$15.2K ﹤0.01% 2374
2016
Q3 		$404K Sell
24,557
-2,500
-9% -$36K ﹤0.01% 2276
2016
Q2 		$386K Buy
+27,057
New +$365K ﹤0.01% 2286

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Nationwide Fund Advisors's CRVS Position: Q4 2017 in Review

Nationwide Fund Advisors sold out of Corvus Pharmaceuticals (CRVS) in Q4 2017, closing a stake of 74,513 shares — an estimated $1.19M sold.

Nationwide Fund Advisors first reported a position in CRVS in Q2 2016 and held it in 6 quarters. The position peaked at $1.19M in Q3 2017. 54 funds tracked by Wall St. Rank hold CRVS as of Q4 2017.

  • Nationwide Fund Advisors reported no remaining Corvus Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Nationwide Fund Advisors sold 74,513 Corvus Pharmaceuticals shares in Q4 2017, an estimated $1.19M.
  • Nationwide Fund Advisors first reported a position in Corvus Pharmaceuticals in Q2 2016 and held it in 6 quarters.
  • Nationwide Fund Advisors's Corvus Pharmaceuticals position peaked at $1.19M in Q3 2017.
  • 54 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q4 2017.

Based on Nationwide Fund Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.